Table 3 Results of the univariate analysis
| Â | HR | 95%CI | p-value |
|---|---|---|---|
Pre-treatment PSA | 1.09 | 0.92–1.29 | 0.341 |
Clinical tumor stage | 1.14 | 0.48–2.71 | 0.765 |
Radiological tumor stage | 1.12 | 0.71–1.75 | 0.627 |
Gleason score | 1.71 | 0.87–3.34 | 0.115 |
Gleason score (< or ≥ 7) | 2.42 | 0.98–5.93 | 0.053 |
Clinical risk group | 1.73 | 0.98–3.03 | 0.055 |
Radiological risk group | 1.17 | 0.78–1.75 | 0.441 |
Percentage of positive biopsies | 1.02 | 0.99–1.05 | 0.191 |
Percentage of positive biopsies (≤ or > 50%) | 2.34 | 0.53–10.15 | 0.257 |
Neo-adjuvant hormone therapy | 1.57 | 0.64–3.87 | 0.323 |
Duration of hormone therapy | 1.01 | 0.84–1.22 | 0.887 |
Apex involvement | 1.16 | 0.44–3.06 | 0.758 |
Midgland involvement | 0.83 | 0.31–2.19 | 0.716 |
Base involvement | 1.26 | 0.47–3.41 | 0.6491 |
D90 | 1.04 | 0.92–1.16 | 0.5592 |
V100 | 2.67 | 0.01–1055.7 | 0.7479 |